Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011.

Original Source

Artemisinin-based therapies are the only effective treatment for malaria, the most devastating disease in human history. To meet the growing demand for artemisinin and make it accessible to the poorest, an inexpensive and rapidly scalable production platform is urgently needed. Here we have developed a new synthetic biology approach, combinatorial supertransformation of transplastomic recipient lines (COSTREL), and applied it to introduce the complete pathway for artemisinic acid, the precursor of artemisinin, into the high-biomass crop tobacco.

Deaths caused by AIDS declined nearly 55% in India in the past eight years, whereas new HIV infections came down by 66% since 2000.

This report provides guidance for countries to enhance the functioning and transparency of the patent system for the timely and affordable access to lifesaving treatment. Affordable access to treatment is closely linked with the aspiration to ensure health and well-being for all, as embodied in the Sustainable Development Goal (SDG).

Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today's vaccines typi

The successful results of a University of Liverpool led drug trial aimed at developing new therapeutic approaches to cancer have been presented at two American medical conferences.

Malaria parasites cause hundreds of millions of infections, and kills hundreds of thousands of people annually, mostly in Africa.

Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the rece

Products of major pharmaceutical firms, including Abbott Healthcare, Cipla and Lupin will be affected by the new price cap

WASHINGTON - Two Israeli companies say they used a specialized 3-D printer to create an environment in which stem cells could grow into a specific tissue.

Pages